WASHINGTON – Novartis (NYSE: NVS) won an order from a U.S. appeals court in Washington on Thursday temporarily blocking drugmaker
1 year ago
WASHINGTON – A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals’ launch of a generic version of Novartis’ (NYSE: NVS)
ZURICH – On Thursday, Novartis (NYSE: NVS), the Swiss pharmaceutical group, said it was winding up MorphoSys sites in Germany
Novartis (NYSE: NVS) failed to convince a U.S. appeals court on Wednesday to halt MSN Pharmaceuticals’ proposed generic of Novartis’
FRANKFURT – Novartis (NYSE: NVS) raised its medium-term sales guidance on Thursday to 6% annual growth through 2028, driven by
ZURICH – Novartis (NYSE: NVS) expects to increase its annual sales by at least 5% per year in the coming
FRANKFURT – Novartis, the Swiss drugmaker, raised its 2024 earnings guidance on Tuesday for the third time buoyed by wider
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, will pay Monte Rosa Therapeutics (NASDAQ: GLUE) $150 million upfront payment for a
BERLIN – Switzerland’s COMCO competition commission terminated an investigation against Novartis (NYSE: NVS) into possibly using blocking patents, without consequences,
On Saturday, Novartis (NYSE: NVS), a Swiss drugmaker, said it had received a binding offer from Germany’s Siemens Healthineers to
On Monday, Novartis (NYSE: NVS) and Viatris (NASDAQ: VTRS) were hit with a federal lawsuit in Maryland by the family
FRANKFURT – Swiss drugmaker Novartis (NYSE: NVS) raised its 2024 earnings guidance for the second time on Thursday, driven by
2 years ago
